Friday, June 19, 2009
Potential new option for treating C. difficile
A small case series in Clinical Infectious Diseases describes four patients with severe refractory Clostridium difficile infection successfully treated with IV tigecycline. Three of the patients had failed standard therapy with metronidazole and vancomycin. This is potentially important given the rising incidence in C. difficile. Unfortunately, my experience with this antibiotic for other indications has been poor since most of my patients could not tolerate the severe nausea it causes.
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati... -
This is a guest post by Jorge Salinas, MD, Hospital Epidemiologist at the University of Iowa Hospitals & Clinics. There is virtually no...
-
I’m surprised that we can’t stop arguing about the modes of SARS-CoV-2 transmission, despite the fact that most experts (including our frie...
No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.